Affordable Access

deepdyve-link
Publisher Website

[Targeting KRAS pathway in NSCLC therapy].

Authors
  • Le Moulec, S
  • Loriot, Y
  • Soria, J-C
Type
Published Article
Journal
Bulletin du Cancer
Publisher
Elsevier
Publication Date
Dec 01, 2009
Volume
96 Suppl
Identifiers
DOI: 10.1684/bdc.2009.0998
PMID: 20034872
Source
Medline
License
Unknown

Abstract

KRAS mutations are currently the most frequently mutated oncogenes in non-small cell lung cancers (NSCLC). A growing body of evidence suggests that targeting RAS could be an efficient strategy in NSCLC. Several approaches have been developed to target either RAS protein or downstream effectors such as RAF or MEK. First clinical trials evaluating farnesyltransferases inhibitors have led to unsuccessful results. However, targeting RAF and MEK could be a more efficient approach in NSCLC.

Report this publication

Statistics

Seen <100 times